Skip to content
NxGEN Vector Solutions, LLC
  • About us
  • Our Technology
  • The Science
  • Cardiac Gene Therapy
  • Newsroom
  • Contact Us

October 6th, 2020 - October 6, 2020 — NxGEN Vector Solutions received trademark protection for the NxGEN logo.

NxGen Vector Solutions

Share this:

  • Share on X (Opens in new window) X
  • Share on Facebook (Opens in new window) Facebook

Related

Post navigation

September 8, 2020 – Partner with NxGEN Vector Solutions to apply NxGEN Technology to your AAV vectors and eliminate the immune response that limits transgene durability. Learn more in the May issue of Genetic Engineering & Biotechnology News (GEN Magazine) on pages 10-11.
November 19, 2020 – You’ve probably seen the plethora of papers and presentations in 2020 demonstrating that stable transgene expression in human clinical trials is dependent on the AAV vector genome CpG motifs. This confirms the preclinical studies performed nearly 8 years ago by Dr. Susan Faust and Dr. Joseph Rabinowitz–both members of NxGEN Vector Solutions–and pioneers of CpG-depleted AAV vectors (NxGEN Technology). The desirability of CpG depletion of AAV vectors for the purpose of reducing the immune response to the vector and establishing long-term transgene expression is very hot in the manufacturing sector and of great interest to gene therapists.

NxGEN Vector Solutions, LLC
455 Massachusetts Ave., N.W., Suite 369
Washington, D.C. 20001
p: 202.765.7475
www.nxgenvectorsolutions.com

About Us
• Our Founder and Members
Our Technology
• The Science
• The Technical Details
Newsroom
Construct Design & Consulting
Contact Us
• Privacy
  Facebook
  Twitter

copyright © 2018 NxGEN Vector Solutions, LLC

 

Loading Comments...
 

You must be logged in to post a comment.